CHEMOCENTRYX
ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.
CHEMOCENTRYX
Industry:
Biotechnology Health Care Medical Device
Founded:
1997-01-01
Address:
San Carlos, California, United States
Country:
United States
Website Url:
http://www.chemocentryx.com
Total Employee:
101+
Status:
Active
Contact:
+1.650.210.2900
Email Addresses:
[email protected]
Total Funding:
634.34 M USD
Technology used in webpage:
SPF SSL By Default Mobile Non Scaleable Content Amazon IPv6 Google Maps ReCAPTCHA Microsoft Azure DNS Google Maps API Apple Mobile Web App Capable
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Gelesis
Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients.
Intarcia Therapeutics
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Myomo
Myomo develops devices with myoelectric prosthetic technology to restore the mobility of individuals with muscle weakness.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - ChemoCentryx
Alta Partners
Alta Partners investment in Series E - ChemoCentryx
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series E - ChemoCentryx
Glaxo Group
Glaxo Group investment in Series E - ChemoCentryx
HealthCap
HealthCap investment in Series E - ChemoCentryx
Glaxo Group
Glaxo Group investment in Series D - ChemoCentryx
OrbiMed
OrbiMed investment in Series D - ChemoCentryx
Gimv
Gimv investment in Series D - ChemoCentryx
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series D - ChemoCentryx
Alta Partners
Alta Partners investment in Series D - ChemoCentryx
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-11 | ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer |
Official Site Inspections
http://www.chemocentryx.com Semrush global rank: 4.64 M Semrush visits lastest month: 2.14 K
- Host name: cloudproxy10158.sucuri.net
- IP address: 192.124.249.158
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ChemoCentryx"
ChemoCentryx - Crunchbase Company Profile & Funding
Organization. ChemoCentryx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ChemoCentryx is a biopharmaceutical company that develops medications for inflammatory …See details»
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
Aug 4, 2022 Acquisition Includes TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease . Tavneos Adds to Amgen 's Decades-Long Leadership in …See details»
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF …
Oct 20, 2022 TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio. THOUSAND OAKS, Calif., Oct. …See details»
ChemoCentryx - Funding, Financials, Valuation & Investors
ChemoCentryx is a biopharmaceutical company that develops medications for inflammatory and autoimmune diseases and cancer. Search Crunchbase. Start Free Trial . ... How much funding …See details»
ChemoCentryx Company Profile - Office Locations, Competitors
Mar 3, 2022 ChemoCentryx is a biopharmaceutical company commercializing and developing medications for inflammatory and autoimmune diseases and cancer. It focuses on orphan and …See details»
ChemoCentryx Announces Changes to its Board of Directors
May 31, 2022 Dr. Wheadon holds a M.D. from Johns Hopkins University School of Medicine and an A.B. in Biology from Harvard University. He completed his postdoctoral training in …See details»
Amgen bets on ChemoCentryx's rare disease drug in $3.7 billion deal
Aug 4, 2022 The company, which kept its full-year adjusted profit forecast unchanged at between $17 and $18 per share, would pay $52 in cash for each share of ChemoCentryx, a …See details»
Amgen to Acquire ChemoCentryx for $3.7B, Bolstering …
Aug 5, 2022 Last month, ChemoCentryx presented positive safety results from the first 13 patients enrolled across four dose cohorts: (30 mg, 60 mg, 120 mg, and 180 mg) as of April …See details»
Amgen Will Acquire Chemocentryx in $4 Billion Deal - BioPharm …
On Aug. 4, 2022, Amgen announced a definitive agreement to acquire ChemoCentryx, a biopharmaceutical company specializing in therapeutics to treat autoimmune diseases, …See details»
Amgen bets almost $4B on a biotech and its inflammation drugs
Aug 4, 2022 Per deal terms, Amgen has offered to acquire ChemoCentryx at $52 per share, reflecting a 116% premium from the roughly $24 shares traded at by market’s close …See details»
Amgen continues buying spree with $3.7B ChemoCentryx deal
Aug 4, 2022 ChemoCentryx plans to start a phase 3 test of Tavneos in hidradenitis suppurativa and a new study in lupus nephritis later this year, the SVB team noted. The company also has …See details»
ChemoCentryx Announces Appointment of Jennifer L. Herron to …
Jul 5, 2022 ChemoCentryx, Inc.-- Ms. Herron brings more than 25 years of therapeutics commercial experience and brand management to ChemoCentryx Board --SAN CARLOS, …See details»
Amgen Buys ChemoCentryx for $3.7 Billion
Aug 5, 2022 Amgen will acquire rare disease drug developer ChemoCentryx for $52 per share in cash, making the deal worth approximately $3.7 billion. “The acquisition of ChemoCentryx …See details»
Amgen bided its time to snatch up ChemoCentryx - Fierce Pharma
Sep 1, 2022 By ChemoCentryx’s estimate, Tavneos, in its currently approved ANCA vasculitis indication, could cross the blockbuster threshold in 2031 and reach peak sales of $1.14 billion …See details»
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
Aug 4, 2022 ChemoCentryx and its directors, executive officers and certain other members of management and employees may be deemed to be participants in soliciting proxies from its …See details»
ChemoCentryx's drug gets U.S. FDA nod for treating rare …
Oct 8, 2021 ChemoCentryx Inc said on Friday the U.S. health agency approved its lead drug for treating a rare, fatal autoimmune disease, sending the biopharmaceutical company's shares …See details»
Amgen Successfully Completes Acquisition of ChemoCentryx
Oct 25, 2023 TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio. THOUSAND OAKS, Calif., (Oct. …See details»
ChemoCentryx Announces FDA Approval of TAVNEOSâ„¢ (avacopan)
Oct 8, 2021 ChemoCentryx will host a conference call and webcast today, October 8, 2021 at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. To participate by telephone, please dial (877) …See details»
ChemoCentryx Announces Upcoming Presentations for Orally …
ChemoCentryx Poster Presentations at SITC 37th Annual Meeting (November 8-12, 2022): Results From an Ongoing Open-Label, Multicenter, Phase 1 Trial of CCX559, an Orally …See details»
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF …
Oct 20, 2022 About ChemoCentryx ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases …See details»